StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

Analysts at StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the stock.

Trinity Biotech Stock Down 7.9 %

Shares of NASDAQ:TRIB opened at $0.75 on Wednesday. The stock has a market capitalization of $13.59 million, a PE ratio of -0.33 and a beta of 1.03. The firm’s 50 day moving average price is $0.85 and its 200-day moving average price is $1.32. Trinity Biotech has a twelve month low of $0.73 and a twelve month high of $3.55.

Institutional Investors Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 78.97% of the stock is currently owned by hedge funds and other institutional investors.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.